151 |
Avaliação dos efeitos antineoplásicos da inibição do NF-kB pelo DHMEQ (Dehidroximetilepoxiquinomicina) em linhagens celulares de meduloblastoma / Evaluation of anti-neoplastic effects of NF-kB inhibition by DHMEQ (Dehidroximetilepoxiquinomicina) in medulloblastoma cell linesPriscila Maria Manzini Ramos 30 May 2014 (has links)
Meduloblastoma é um câncer do sistema nervoso central, altamente invasivo, de origem embrionária, localizado no cerebelo. É mais comum em crianças e corresponde a aproximadamente 20% de todos os tumores intracranianos pediátricos. Os tratamentos mais utilizados são cirurgia e quimioterapia, sendo que a radioterapia é aplicada somente em crianças com mais de 3 anos devido aos seus efeitos colaterais. Diversos estudos têm mostrado o papel do NF-B na regulação de genes envolvidos com o processo neoplásico. NF-B é um fator de transcrição chave na regulação da resposta imune e no processo de inflamação e está envolvido na regulação da transcrição de um grande número de genes relacionados ao processo de tumorigênese, além de ser constitutivamente ativo em diversos tipos de câncer, sendo um importante potencial alvo terapêutico. O DHMEQ (Dehidroximetilepoxiquinomicina) é uma droga que inibe a translocação do NF-B do citoplasma para o núcleo, inibindo assim a sua atuação como ativador transcricional. Vários trabalhos tem mostrado os efeitos antineoplásicos do DHMEQ em inúmeros tipos tumorais, entretanto, não há trabalhos que evidenciem esses efeitos em meduloblastoma. Assim, o presente estudo objetivou avaliar os efeitos dessa droga nas linhagens UW402, UW473 e ONS-76 de meduloblastoma pediátrico através de estudos funcionais e moleculares. Os resultados de proliferação demostraram uma significativa diminuição do crescimento celular nas linhagens de meduloblastoma, inibindo cerca de 80, 70 e 60% nas linhagens UW402, UW473 e ONS-76, respectivamente, na dose de 20 g/mL, e apresentou um IC50 de 10g/mL em 48h para as linhagens UW402 e UW473 e em 72h na linhagem ONS-76. Adicionalmente, elevou o nível de apoptose para 50, 17 e 31% nessas linhagens, respectivamente, inibiu fortemente a capacidade clonogênica, a migração e a invasão celular nas três linhagens e foi sinérgico na combinação com outros quimioterápicos em grande parte dos pontos de combinação, além de radiossensibilizar fortemente as três linhagens. Os resultados são congruentes com o potencial efeito antitumoral de DHMEQ. / Medulloblastoma is a cancer of the central nervous system, highly invasive, of embryonic origin, located in the cerebellum. It is more common among children and accounts for approximately 20% of all pediatric intracranial tumors. The most common treatments are surgery and chemotherapy, and radiotherapy is only to children older than 3 years old due to its side effects. Several studies have demonstrated the role of NF-B in the regulation of genes involved in the neoplastic process. NF-B is a key transcription factor in the regulation of immune response and inflammation process, and it is involved in the transcriptional regulation of a large number of genes related to the tumorigenesis process, and constitutively active in many types of cancer, being an important potential therapeutic target. DHMEQ (Dehidroximetilepoxiquinomicina) is a drug that inhibits the translocation of NF-B from the cytoplasm to the nucleus, thus inhibiting its activity as a transcriptional activator. Several studies have shown the antineoplastic effects of DHMEQ in numerous tumor types, however, there is no surveys that have tested their effects in medulloblastoma. Thus, the present study aimed to evaluate the effects of this drug in UW402, UW473 and ONS-76 pediatric medulloblastoma cell lines through functional and molecular studies. The proliferation test results demonstrated a significant decrease in the cell growth in the medulloblastoma cell lines, inhibiting approximately 80, 70 and 60% for UW402, UW473 and ONS-76, respectively, at a dose of 20g/mL, and showed an IC50 of 10g/mL at 48h for UW402 and UW473 and at 72h in ONS-76. Additionally, increased the level of apoptosis to 50, 17 and 31% in these cell lines, respectively, strongly inhibited the clonogenic capacity, the migration and cell invasion in the three lines and it was synergistic in combination with other chemotherapeutic agents in most combination points, and radiosensitization strongly the three cell lines. The results are congruent with the potential antitumor effect of DHMEQ.
|
152 |
Identifying Targetable Liabilities in Ewing SarcomaVallurupalli, Mounica 07 July 2014 (has links)
Background: Despite multi-modality therapy, the majority of patients with metastatic or recurrent Ewing sarcoma (ES), the second most common pediatric bone malignancy, will die of their disease. ES tumors express aberrantly activated ETS transcription factors through translocations that fuse the EWS gene to ETS family genes FLI1 or ERG. The aberrant activation of ETS transcription factors promotes malignant transformation and proliferation. While, FLI1 or ERG cannot be readily targeted, there is an opportunity to deploy functional genomics screens, to develop novel therapeutic approaches by identifying targetable liabilities in EWS/FLI1 dependent tumors.
Materials and Methods: We performed a near whole-genome pooled shRNA screen in a panel of five EWS/FLI1 dependent Ewing sarcoma cell lines and one EWS/ERG cell line to identify essential genes. Essential genes were defined as those genes whose loss resulted in reduced viability selectively in ES cells compared to non-Ewing cancer cell lines. Essential hits were subsequently validated with genomic knockdown and chemical inhibition in vitro, followed by validation of the on-target effect of chemical inhibition. Next, we determined the in vivo effects of small-molecule inhibition on survival and tumor growth in NOD scid gamma (NSG) mice with established subcutaneous ES xenografts.
Results: Top hits in our screen that could be readily targeted by small-molecule inhibitors, and thus have potential for rapid clinical validation, were selected for further investigation. These hits included IKBKE, CCND1 and CDK4. IKBKΕ, a non-canonical IKK with an oncogenic role in breast cancer, was one of the top kinase hits in the screen. IKBKΕ shares significant homology to TBK1, another non-canonical IKK that is essential in k-RAS dependent lung cancer. We validated IKBKE through small-molecule inhibition of IKBKE/TBK1 and shRNA based knockdown. Ewing sarcoma cell lines are sensitive to low micromolar concentrations of two IKBKE/TBK1 inhibitors (CYT387 and MRT67307). Additionally, in a panel of ES cell lines, knockdown of IKBKE resulted in decreased growth and impaired colony formation. These observations, paired with impairment of NF-κB nuclear localization following CYT387 treatment suggests that non-canonical IKK mediated signaling may be essential in Ewing sarcoma. We further validated these results through inhibition of IKBKE/TBK1 in in vivo xenograft models treated with 100 mg/kg/day of CYT387. Treatment over the course of twenty-nine days resulted in a significant increase in survival (p-value = 0.0231) and a significant decrease (p-value = 0.036) in tumor size after fifteen days of treatment.
CDK4 and CCND1 are highly expressed in Ewing sarcoma as compared to other tumor types. shRNA mediated knockdown of CDK4 and CCND1 resulted in impaired viability and anchorage independent growth. Furthermore, treatment of Ewing sarcoma cell lines with a highly selective CDK4/6 inhibitor, LEE011, resulted in decreased viability (IC50 range of 0.26-18.06 μM), potent G1 arrest in six of eight EWS/FLI1 containing Ewing sarcoma lines tested and apoptosis in a panel of four highly sensitive lines. Administration of 75 mg/kg/day and 250 mg/kg/day of LEE011 in NSG mice with Ewing xenografts resulted in significant impairment of tumor growth, (p-value <0.001 for both treatment arms), as compared to vehicle control.
Conclusions: These studies suggest a role for the targeting of IKBKE and CDK 4/6 in Ewing sarcoma, findings with immediate clinical relevance for patients with this malignancy, because small-molecule inhibitors of these proteins have already entered clinical trial for other disease indications.
|
153 |
Genetic and Pharmacologic Inhibition of Cellular Inhibitor of Apoptosis 1 (cIAP1) Protein Expression Protects Against Denervation-Induced Skeletal Muscle Atrophy In VivoLejmi Mrad, Rim January 2016 (has links)
Skeletal muscle atrophy is a debilitating condition caused by pathological conditions including cancer cachexia, disuse and denervation. Disuse atrophy is characterized by reduction in fiber size, fiber-type change and induction of markers of atrophy such as MuRF1 and Fn14. Recent studies have focused on understanding the fundamental role of signalling pathways and the proteolytic system in response to muscle atrophy. Unfortunately the exact mechanisms behind atrophy remain poorly understood. I recently demonstrated that cIAP1 and/or cIAP2 proteins are critical regulators of NF-kB activation, which has been shown to be involved in skeletal muscle atrophy. Here, I used genetic and pharmacological means to investigate the role of cIAP1 in a denervation-induced skeletal muscle atrophy model. Interestingly, I found that upon denervation loss of cIAP1 rescues muscle fiber size, prevents fiber-type changing and inhibits the expression of MuRF1 and Fn14. Moreover, treatment of mice with Smac mimetic compounds (SMC), a novel class of small molecule IAP antagonists, showed successful knockdown of cIAP1 in muscle and protects against denervation-induced muscle atrophy. Taken together, these data reveal that cIAP1 is both a novel mediator of skeletal muscle atrophy and an important therapeutic target.
|
154 |
The Novel Regulatory Roles of TRAPPC9 and L-Plastin in OsteoarthritisHussein, Nazar J. 23 July 2021 (has links)
No description available.
|
155 |
Assoziation psychometrisch erfasster depressiver Symptomatik mit dem Expressionsgrad von NF-kB bei inflammatorischen Erkrankungen des Gastrointestinaltraktes / Association of psychometrically recorded depressive symptoms with the expression level of NF-kB in inflammatory diseases of the gastrointestinal tractVonhören, Lara Marie 16 June 2020 (has links)
No description available.
|
156 |
Viral Sensitizers Potentiate the Infection of Cancer Cells Via NF-kBPhan, Michael 20 May 2020 (has links)
Genetically engineered oncolytic viruses (OVs) have been proven to be effective anti-cancer agents. However, the heterogeneity of tumours and obligate attenuation of OVs to achieve safety can limit their efficacy. Our lab has previously shown that diverse small molecules, which we have termed “Viral Sensitizers”, used in combination with OVs can potentiate the infection of cancer cells by OVs over 1000-fold in some cases, resulting in cancer-specific killing in both in vitro and in vivo tumour models. We observed that a subset of viral sensitizer compounds ultimately acts by reducing the expression of IFNb, thereby inhibiting antiviral signaling. Here, we aimed to further refine the mechanism of action of this class of compounds. Our results suggest that VSe1 and more stable analogs such as VSe1-28 inhibit nuclear accumulation of NF-kB p65 and expression of various antiviral cytokines including, TNFa, IL-6, IFITM1, and MX2 in multiple oncolytic VSV-resistant cancer cell lines but not in normal cells. This was also observed in vivo in CT26wt immune-competent mouse tumour models, where our group has already demonstrated the therapeutic benefit of combining VSe1-28 with oncolytic VSV. Using various biochemical methods, we have determined that VSe1 and its analog VSe1-28 lead to these effects at least in part through covalent modification of NF-kB p65. In sum, this study provides a new understanding of how these novel viral sensitizers work at the molecular level. This new understanding will not only aid in the discovery and development of improved molecules but also their clinical translation in combination with oncolytic viruses.
|
157 |
Étude de la régulation du facteur de transcription NF-kB dans l'infection par le RSVMartel, Alexis 02 1900 (has links)
No description available.
|
158 |
Regulation of Protein Arginine Methyl Transferase 5 by Novel Serine 15 Phosphorylation in Colorectal CancerHartley, Antja-Voy Anthoneil 01 1900 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / The overexpression of protein arginine methyltransferase 5 (PRMT5) is strongly correlated to poor clinical outcomes for colorectal cancer (CRC) patients. Previously, we demonstrated that PRMT5 overexpression could substantially augment activation of NF-κB via methylation of arginine 30 (R30) on its p65 subunit, while knockdown of PRMT5 showed the opposite effect on the transcriptional competence of p65. However, the precise mechanisms governing this PRMT5/NF-κB axis are still largely unknown. We report a novel finding that PRMT5 is phosphorylated on serine 15 (S15) in response to interleukin-1β (IL-1β) stimulation. Overexpression of the serine-to-alanine mutant of PRMT5 (S15A-PRMT5), in either HEK293 cells or HT29, DLD1 and HCT116 CRC cells attenuated NF-κB activation compared to wild type (WT)-PRMT5, confirming that S15 phosphorylation is critical for the activation of NF-κB by PRMT5. Furthermore, we found that overexpression of S15A-PRMT5 mutant attenuated the expression of a subset of NF-κB target genes through decreased p65 occupancy at their respective promoters. Importantly, the S15A-PRMT5 mutant also reduced IL-1β-induced methyltransferase activity of PRMT5 as well as its ability to form a complex with p65. Finally, we observed that the S15A-PRMT5 mutant diminished the growth, migratory and colony-forming abilities of CRC cells compared to the WT-PRMT5. Collectively, our findings provide strong evidence that novel phosphorylation of PRMT5 at S15 is critical to its regulation of NF-κB and plays an essential role in promoting the cancer-associated functions exerted by the PRMT5/NF-κB axis. Therefore, development of inhibitors to block phosphorylation of PRMT5 at S15 could become a potential novel therapeutic approach to treat CRC. / 2020-10-15
|
159 |
Development of heparin nanoparticles:synthesis, physicochemical/biochemical characterization and application to arthritis therapy / ヘパリンナノ粒子の開発:合成、物理化学的・生物学的評価と関節炎治療への応用Hasan Babazada 24 September 2014 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(薬学) / 甲第18549号 / 薬博第811号 / 新制||薬||238(附属図書館) / 31449 / 京都大学大学院薬学研究科医療薬科学専攻 / (主査)教授 橋田 充, 教授 髙倉 喜信, 教授 佐治 英郎 / 学位規則第4条第1項該当 / Doctor of Pharmaceutical Sciences / Kyoto University / DFAM
|
160 |
Effects of Sodium Methyldithiocarbamate-Induced Oxidative Stress on Nf-Kappa B ActivationGadson, Monica Cherie 11 August 2012 (has links)
Sodium methyldithiocarbamate (SMD) is commonly reported to cause health risks in humans. Previous reports indicate SMD causes oxidative stress, which can contribute to the activation of NF-êB and cause other characteristics of inflammatory responses to be altered. Almost all pro-inflammatory cytokines require NF-êB activation for full expression and development of an innate immune or inflammatory response. This study evaluated NF-êB activation, providing new information regarding reactive oxygen in macrophages from SMD-treated mice. Studies were conducted in which NF-êB reporter mice were treated with lipopolysaccharide (LPS), SMD, buthionine sulfoximine (BSO), and N-acetyl cysteine (NAC). BSO depletes glutathione (GSH) and increases oxidative stress, whereas NAC spares GSH by acting as a precursor for rapid synthesis to replace oxidized GSH. The work here indicates that NF-êB is not affected directly by increased or decreased reactive oxygen species (ROS), and oxidative stress is not the major mechanism by which SMD inhibits inflammatory responses.
|
Page generated in 5.5554 seconds